suMMARY While rheumatoid-factor-producing haemolytic plaque-forming cells (RF-PFC) et al., 1978).
We have recently reported on drugs affecting the production and release of an autoantibody, rheumatoid factor (RF), from human peripheral blood lymphocytes (Vaughan et al., 1976) . The RF is detected in a plaque-forming cell (PFC) assay. RF-PFC are apparently very sensitive to only slightly adverse conditions in vitro. For instance, maximal numbers of RF-PFC are found only when full tissue culture medium is used in the agarose phase of the assay, rather than the simpler buffers that are generally used in other PFC assays (Vaughan et al., 1976) . We observed that RF-PFC can be inhibited easily by agents interfering with protein synthesis, cycloheximide, or puromycin by a microtubule disrupting agent, vinblastine, and by a membrane stabilising agent, D-propranolol .
We were interested in whether these characteristics of the RF-PFC system were different from what we would find in another, more familiar PFC assay, the anti-sheep red cell (SRC) PFC. Jerne (1974) has shown in the anti-SRC system that antibody secretion is maintained at full rate at 370C but is Accepted for publication 25 stopped by lowering the temperature. Secretion of antibody lags about 30 minutes behind synthesis. He also showed that incubation of the spleen cell suspension at 370C in the presence of cycloheximide and puromycin at 10 ,ug per ml reduced the number of plaques. Although synthesis of antibody was probably completely inhibited, the cells continued to secrete antibody for some hours, which was antibody synthesised before exposure of the inhibitors of protein synthesis. Plaque formation in agar was thus mainly due to active secretion of antibody from viable cells.
We have therefore re-examined mouse spleen cells making a primary anti-SRC response to SRC injected intravenously 5 days previously by looking at the effects of cycloheximide and puromycin and also the effects of vinblastine and propranolol. Our results in the anti-SRC system show distinct differences from those found in the RF-PFC system in relation to cycloheximide and propranolol, and we offer some interpretations for the differences noted. Haemolytic plaque assay. 0.5 ml of 0.5 % agarose (Agarose A-37 Indubiose) at 440C was mixed with 0.05 ml of 6.7 % suspension of SRC and 0.05 ml of the cell suspension which had been preincubated for 30 minutes at room temperature with the inhibitor at the appropriate concentration or normal saline as control. The mixture was poured on to precoated microscope slides, the slides were incubated for 60 minutes at 370C in a moist chamber, and then immersed in a 1:10 dilution of guinea-pig complement (Pel-Freeze). After an additional 60 minutes at 370C PFC were enumerated under magnification. Three replicate determinations were made at each concentration.
Rheumatoid factor PFC assay. Peripheral blood lymphocytes were obtained from selected patients with rheumatoid arthritis. These patients had clinically active, seropositive arthritis and had been shown to have high numbers of RF-producing cells in their peripheral blood. The lymphocytes were plaqued for RF-producing cells as described (Vaughan et al., 1976 (Tanimoto et al., 1975) .
Metabolic inhibitors. Puromycin and cycloheximide were obtained from Calbiochem; vinblastine was from Lilly; D-propranolol was from Ayerst.
In performing preincubation studies with drugs we noted a considerable loss of number of PFC in our controls during the preincubations. The loss was dependent on both time and temperature (Fig. 1) (Fig. 2) . Vinblastine, which had suppressed RF-PFC almost completely when added at 10-4 M to the agarose phase of the assay (Table 1 ) also suppressed the anti-SRC PFC (Fig. 4) . The relative degrees of suppression in the 2 antibody systems seemed comparable. Reversibility of the vinblastine effect was evident when vinblastine was preincubated with the lymphocytes but left out of the agar phase, a manoeuvre which resulted in a final concentration of the vinblastine in the agarose which was 10-fold less than it had been during the preincubation phase of the experiment (Fig. 4) . Discussion RF-PFC and anti-SRC PFC differed in their behaviour in cycloheximide and propranolol but not in vinblastine. Vinblastine reduced equally the expression of RF-PFC and anti-SRC PFC. Vinblastine disrupts cytoplasmic microtubles, and presumably this is the mechanism for its inhibiting the PFC in both systems examined.
Cycloheximide was clearly inhibitory of RF-PFC when it was added simply to the agarose phase of the assay. It inhibited the anti-SRC PFC, however, only after prolonged preincubation with the cells. We interpret this to mean that most of the antibodyproducing cells in the immune mouse spleen, at least as initially isolated, have large stores of preformed antibody in them, which are easily released during the agarose phase of the assay. These PFC do not need continued synthesis to make enough antibody for the formation of haemolytic plaques and therefore are not suppressible with inhibitors of protein synthesis. When the spleen cells are preincubated under conditions favouring loss of such cytoplasmic stores of antibody, the remaining PFC increasingly represent cells in which continued new synthesis of antibody is needed for plaque formation. Under these conditions suppression of anti-SRC PFC by cycloheximide is easily demonstrated. RF-PFC, being easily suppressed by cycloheximide without preincubation, would therefore appear to be cells with little in the way of preformed stores of antibody.
Propranolol suppressed RF-PFC but did not suppress the mouse spleen anti-SRC PFC even with the preincubation. We have supposed that propranolol exerts its effect on RF-PFC by way of its membrane-stabilising effects (Nickerson et al., 1975) . Both the D and L forms of propranolol are active in suppression of RF-PFC . Only the L form has the familiar beta adrenergic blocking effect (Nickerson and Collier, 1975) , while both D and L forms have membrane effects. Both prevent capping of membrane immunoglobulin by anti-Fab (Dunne et al., 1978) as is typical for other membrane-stabilising agents (Ryan et al., 1974) . Capping is a means by which B cells can shed their membrane-bound Ig into the environment, and we have wondered whether this is the principal means for RF release from RF-PFC of the peripheral blood. RF-PFC might thereby be much more susceptible to inhibition by membrane-stabilising agents than are splenic plasma cells with their endoplasmic reticulums loaded with antibody ready for easy export.
Obviously the differences we have documented may be related simply to whether the antibodyforming cells are taken from the blood or from the spleen. Or they may conceivably represent species differences. In our previous study , however, we observed that anti-SRC made by human peripheral blood lymphocytes also were not inhibited by propranolol. Species differences therefore are probably not determinant of the propranolol effects. Finally, we may be observing drug differences related to the antibody, being to an exogenous antigen in one instance and an autoantigen in the other.
Of the drugs tested only propranolol has any conceivable use therapeutically. Neither cycloheximide nor vinblastine can be tolerated in the doses needed. In other studies Dunne et al., 1978) we have shown propranolol to be immunosuppressive in vitro in concentrations as low as 2-5 x 10-5 M. However, conventional doses of propranolol give peak plasma levels of only 10-6 M. Possibly massive doses of propranolol, such as have sometimes been given to patients with hypertension (Holland et al., 1976) , could provide effective immunotherapy in RA. Alternatively, congeners of propranolol may be found which would be effective at lower doses. 
